PATENT APPLICATION DOCKET NO.: 3890.1000-000

## JC06 Rec'd PCT/PTO 24 AUG

### IN THE UNITED STATES RECEIVING OFFICE (RO/US) Designated/Elected Office (DO/EO/US)

3. National Stage of

International Application No.:

PCT/GB2003/004050

International Filing Date:

22 September 2003

Earliest Priority Date:

20 September 2002

Applicants:

Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers,

Debra Taylor and Stan Tyms

Title:

BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL

COMPOSITIONS CONTAINING THEM

Attorney's Docket No.: 3890.1000-000

Date:

EXPRESS MAIL LABEL NO. EV 215891094US

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

a & 150

Sir:		0	5182
This Ir	nformation Disclosure Statement is submittunder 37 CFR 1.129(a), or (First/Second submission after Final Rejection)	ed:	
[ X ]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months o national stage in an international application; or before the ma application, including a CPA, or a Request for Continued Exa	iling date of a first office action on the me	
[ ]	under 37 CFR 1.97(c) together with either  [ ] a Statement under 37 CFR 1.97(e)  [ ] a \$180.00 fee under 37 CFR 1.17()  (After the 37 CFR 1.97(b) time period, but before final action	, as checked below, or p), or	irst)
[]	under 37 CFR 1.97(d) together with: [ ] a Statement under 37 CFR 1.97(e) [ ] a \$180.00 fee under 37 CFR 1.17(		

under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

(Filed after payment of issue fee)

Stater	nent Un	<u>der 37 C</u>	CFR 1.97(e)			
[ ]	any co	item of information contained in this Information Disclosure Statement was first cited in ommunication from a foreign patent office in a counterpart foreign application not more hree months prior to the filing of this Information Disclosure Statement; or				
[]	knowl contain 37 CF	item of information contained in this Information Disclosure Statement was cited in a amunication from a foreign patent office in a counterpart foreign application, and, to the wledge of the undersigned, after making reasonable inquiry, no item of information tained in the information disclosure statement was known to any individual designated in CFR 1.56(c) more than three months prior to the filing of this Information Disclosure ement.				
Stater	nent Un	<u>der 37 (</u>		(Patent Terr Applies to orig 2000	n Adjustment) ginal applications (other than design) filed on or after May 29,	
[ ]	comm	unicatio unicatio	n from a foreig on was not recei	n patent off ved by any	e Information Disclosure Statement was cited in a ice in a counterpart application and this individual designated in § 1.56(c) more than thirty Disclosure Statement.	
			•			
[X]	Enclos	sed here	with is form P7	ГО-1449:		
	[X]	Copies	of the cited re	ferences, B1	-B21 and C1-C2, are enclosed.	
		[X]	Copies of issu and are not be		ents and published U.S. applications are not required d.	
	[ ]	U.S. A	pplication No.	, to	enclosed except those entered in prior application, which priority under 35 U.S.C. 120 is claimed. [The of the cited references.]	
	[]	The list	sted references rpart foreign ap	were cited in polication.	n the enclosed International Search Report in a	
	[ X ]	The "c	oncise explana l, under 37 CFI	tion" require R 1.98(a)(3)	ement (non-English references) for reference(s) B9 is satisfied by:	
		[ ]	the explanatio	n provided	on the attached sheet.	
		[ ]	the explanatio	n provided	in the Specification.	
		[ ]	submission of	the enclose	d International Search Report.	
		[ ]	submission of Report and/or	the enclose foreign Off	d English-language version of a foreign Search ice Action.	
		[X]	the enclosed F	inglich lang	uage abstract	

[ ]	Appli	cant requests that the following r	non-published pending applic	cations be considered:
Examiner's Initials				
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
· · · · · · · · · · · · · · · · · · ·		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		Examiner	Date	_
	[ ]	A copy of each above-cited appearance any application filed on the PTO's Image File Wrapper	or after June 30, 2003, which	h has been scanned into
	[ ]	A copy of each above-cited appeared those entered in prior appriority under 35 U.S.C. 120 is	oplication, U.S. Application	nt claims, is enclosed, No. [ ], to which
The Ex	xamine nces we	r is requested to return a copy of ere considered with the next office	the above list of pending appear communication.	plications indicating which
It is re	questec	I that the information disclosed h	nerein be made of record in the	nis application.
Metho	d of pa	yment:		
[ ]	A che the ac	ck for the fee noted above is enc companying Reply. A copy of the	losed, or the fee has been inchis Statement is enclosed.	cluded in the check with
[ ]	Please is enc	e charge Deposit Account 08-038 losed.	30 in the amount of \$[	. A copy of this Statement
[X]	Please	charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.
		I	Respectfully submitted,	
			HAMILTON, BROOK, SMI By Alice O. Carroll Registration No.: 33,542 Telephone: (978) 341-0136 Facsimile: (978) 341-0136	of the second
~		04.740.0400		

Concord MA 01742-9133
Dated: Hyper 34, 3005

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3890.1000-000		APPLICATION NO. 10/528,250	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Malcolm Carter  FILING DATE June 21, 20		05	
August 23, 2005	EXAMINER	CONF	IRMATION NO.	GROUP
(Use several sheets if necessary)				

		U.S	S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	Al	5,776,930	07-07-1998	Lynch, Jr., et al.
	A2	6,436,971 B2	08-20-2002	DeMarsh, et al.
	Al	5,593,988	01-14-1997	Tahara, et al.
	A4	5,218,114	06-08-1993	Bock, et al.
	A <b>8</b>	5,220,018	0,6-15-1993	Bock, et al.
	A6	4,988,692	01-19-1991	Gasc, et al.
	A7			
	A8			
	A\$			
	A10			
	All			
	All			
	A13			
	A16			
	A15			
	A16			
	A19			
	A18			
	A19			
	A20			·
	A21			
	A20			
	A23			
	A23			
	A25			

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

August 23, 2005

(Use several sheets if necessary)

 ATTORNEY DOCKET NO. 3890.1000-000	 LICATION NO. 528,250	
FIRST NAMED INVENTOR Malcolm Carter	FILING DATE June 21, 2005	

EXAMINER CONFIRMATION NO. GROUP

	F	OREIGN PATENT D	OCUMENTS		
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSI YES	ATION NO
В1	EP 0 167 919 A2	01-15-1986	Merck & Co., Inc.		
В2	EP 0 434 364 A2	06-26-1991	Merck & Co., Inc.		
В1	EP 0 475 231 A1	03-18-1992	F. Hoffmann-La Roche AG		
Ві	EP 0 508 797 A1	10-14-1992	Merck & Co., Inc.		
В5	EP 0 508 797 A1	10-14-1992	Merck & Co., Inc.		
В6	EP 0 523 845 A2	01-20-1993	Merck & Co., Inc.		
В9	WO 98/18473	05-07-1998	Merck & Co., Inc.		
В8	CN1338456	03-06-2002	Ins. of Medical Materials Chin (CN)	(abstract only)	
В9	WO 00/28947	05-25-2000	Sanofi-Synthelabo	abstract	
B10	WO 99/19306	04-22-1999	Board of Regents, The University of Texas System		
B11	KR212435	08-02-1999	Korea Res Inst Chem Tech (KR)		
B12	WO 98/00406	01-08-1998	Merck & Co., Inc.		
B13	WO 95/14470	06-01-1995	Merck & Co., Inc.		
B14	WO 93/11771	06-24-1993	Cocensys, Inc.		
B15	WO 93/07129	04-15-1993	Yoshitomi Pharmaceutical Industries, Ltd.	(abstract only)	
B16	EP 0 421 802 A2	04-10-1991	Merck & Co., Inc.		
B17	EP 0 284 256 A1	09-28-1988	Merck & Co., Inc.		
B18	WO 00/66106	11-09-2000	The Regents of the University of Michigan		
B19	JP 02-215774	08-28-1990	Roussel Uclaf	abstract	
B20	EP 0 638 560 A1	02-15-1995	Yoshitomi Pharmaceutical Industries, Ltd.		
B21	WO 02/40023 A1	05-23-2002	SmithKline Beecham Corporation		

EXAMINER	DATE CONSIDERED

ATTORNEY DOCKET NO. 3890.1000-000	APPLICATION NO. 10/528,250		
FIRST NAMED INVENTOR Malcolm Carter  FILING DATE June 21, 20		005	
EXAMINER	CONFI	IRMATION NO.	GROUP
	3890.1000-000  FIRST NAMED INVENTOR  Malcolm Carter	3890.1000-000 10/ FIRST NAMED INVENTOR Malcolm Carter	3890.1000-000 10/528,250  FIRST NAMED INVENTOR Malcolm Carter FILING DATE June 21, 20

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CI	Del Giudice, et al., Chemical Abstract 97:23755 CA, "Synthesis of 2- and 3-amino-1, 4-benzodiazepines," Farmaco, Edizione Scientifica 37(5):434-452 (1982).
C2	Kelsey, R., et al., "Synthesis, Resolution and Evaluation of Small Molecule Inhibitors of Respiratory Syncytial Virus," Presented at 44th ICAAC, Oct. 30-Nov 2, 2004.
СЗ	
C4	
C5	
C6	
C7	
C8	
C9	
C10	
CII	
C12	
C13	
C14	
C15	

I	EXAMINER	DATE CONSIDERED
ı		DATE CONSTRUED
ı		
L		